Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luis Puig

Showing results (71-80 of 121) with videos related to

Pageof 13
Sort By:
The Journal of Dermatological Treatment|January 19, 2012
The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial)Robert Strohal, Luis Puig, Edgardo Chouela, et al.
Journal of the American Academy of Dermatology|November 19, 2021
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasisAndrew Blauvelt, Tsen-Fang Tsai, Richard G Langley, et al.
Journal of the American Academy of Dermatology|May 14, 2023
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trialBruce Strober, Carle Paul, Andrew Blauvelt, et al.
The Journal of Dermatological Treatment|November 29, 2013
Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritisLuis Puig, Robert Strohal, M Elaine Husni, et al.
Frontiers in Medicine|February 13, 2023
Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetesAlexander Egeberg, Joseph F Merola, Knut Schäkel, et al.
Frontiers in Medicine|March 28, 2023
Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetesAlexander Egeberg, Joseph F Merola, Knut Schäkel, et al.
Journal of the American Academy of Dermatology|May 28, 2018
Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 studyCraig Leonardi, Catherine Maari, Sandra Philipp, et al.
Journal of the American Academy of Dermatology|December 26, 2021
The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasisCaitriona Ryan, Luis Puig, Carla Zema, et al.
Minerva Medica|May 14, 2024
The "Burden of Skin Diseases" Project: a population-based study on 44,689 participants from 27 European countriesCarle Paul, Alexander J Stratigos, Tamar Nijsten, et al.
The Journal of Rheumatology. Supplement|June 3, 2019
Best-practice Indicators in Psoriatic Disease CarePhilip S Helliwell, Guillaume Favier, Dafna D Gladman, et al.
Pageof 13

Showing results (71-80 of 121) with videos related to

Sort By:
Pageof 13
The Journal of Dermatological Treatment|January 19, 2012
The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial)Robert Strohal, Luis Puig, Edgardo Chouela, et al.
Journal of the American Academy of Dermatology|November 19, 2021
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasisAndrew Blauvelt, Tsen-Fang Tsai, Richard G Langley, et al.
Journal of the American Academy of Dermatology|May 14, 2023
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trialBruce Strober, Carle Paul, Andrew Blauvelt, et al.
The Journal of Dermatological Treatment|November 29, 2013
Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritisLuis Puig, Robert Strohal, M Elaine Husni, et al.
Frontiers in Medicine|February 13, 2023
Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetesAlexander Egeberg, Joseph F Merola, Knut Schäkel, et al.
Frontiers in Medicine|March 28, 2023
Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetesAlexander Egeberg, Joseph F Merola, Knut Schäkel, et al.
Journal of the American Academy of Dermatology|May 28, 2018
Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 studyCraig Leonardi, Catherine Maari, Sandra Philipp, et al.
Journal of the American Academy of Dermatology|December 26, 2021
The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasisCaitriona Ryan, Luis Puig, Carla Zema, et al.
Minerva Medica|May 14, 2024
The "Burden of Skin Diseases" Project: a population-based study on 44,689 participants from 27 European countriesCarle Paul, Alexander J Stratigos, Tamar Nijsten, et al.
The Journal of Rheumatology. Supplement|June 3, 2019
Best-practice Indicators in Psoriatic Disease CarePhilip S Helliwell, Guillaume Favier, Dafna D Gladman, et al.
Pageof 13